RAPT Therapeutics Inc [RAPT] stock is trading at $2.72, up 11.02%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RAPT shares have gain 23.64% over the last week, with a monthly amount glided 44.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
RAPT Therapeutics Inc [NASDAQ: RAPT] stock has seen the most recent analyst activity on May 14, 2024, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Guggenheim downgraded its rating to Neutral on May 10, 2024. On May 10, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $4 on the stock. UBS downgraded its rating to a Neutral and decreased its price target to $10 on February 22, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $10 on February 21, 2024. JP Morgan downgraded its rating to Neutral for this stock on February 21, 2024, and downed its price target to $15. In a note dated February 21, 2024, H.C. Wainwright downgraded an Neutral rating on this stock.
RAPT Therapeutics Inc [RAPT] stock has fluctuated between $1.64 and $27.35 over the past year. Currently, Wall Street analysts expect the stock to reach $42.2 within the next 12 months. RAPT Therapeutics Inc [NASDAQ: RAPT] shares were valued at $2.72 at the most recent close of the market. An investor can expect a potential return of 1451.47% based on the average RAPT price forecast.
Analyzing the RAPT fundamentals
Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -24.39%, Pretax Profit Margin comes in at -22.77%, and Net Profit Margin reading is -22.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.95, Equity is -0.86 and Total Capital is -1.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.33 points at the first support level, and at 1.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.21, and for the 2nd resistance point, it is at 3.71.
Ratios To Look Out For
For context, RAPT Therapeutics Inc’s Current Ratio is 8.14. As well, the Quick Ratio is 8.14, while the Cash Ratio is 2.51.
Transactions by insiders
Recent insider trading involved Brockstedt Dirk G., CHIEF SCIENTIFIC OFFICER, that happened on Jan 05 ’24 when 898.0 shares were sold. Chief Medical Officer, HO WILLIAM completed a deal on Dec 21 ’23 to sell 2500.0 shares. Meanwhile, Chief Medical Officer HO WILLIAM sold 1500.0 shares on Nov 28 ’23.
